Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact Us
Early Edition  //  Current Issue  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited

Medicine Research ›› 2021, Vol. 5 ›› Issue (1): 200020-200020.DOI: 10.21127/yaoyimr20200020

Special Issue: Anticancer Agents

• Minireview •     Next Articles

Recent Advances on Interaction Targets for Anticancer Activity of Caffeine

Titi Liu,a,b Chengting Zi,a,b Xuanjun Wang,a,b,c Jun Sheng,*,a,c and Huanhuan Xu*,a,b   

  1. a Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, Yunnan 650201, China
    b College of Science, Yunnan Agricultural University, Kunming, Yunnan 650201, China
    c State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Kunming, Yunnan 650201, China
  • Received:2020-12-27 Revised:2021-01-09 Online:2021-01-20 Published:2021-01-20
  • Contact: Email: shengj@ynau.edu.cn (J. S.), xuhuan1017@163.com (H. X.)
  • Supported by:

Abstract: Caffeine (1,3,7-trimethylxanthine) is the most frequently ingested neuroactive drug in the world and has enigmatic effects on tumor cells. Convincing evidence from in vitro, animal and human studies suggests that caffeine can inhibit cancer development and progression. Caffeine can easily pass through biological mem-branes and cross the blood-brain barrier, and it is thereby possible to bind to extracellular or intracellular molecules to exert its functions. This review mainly focuses on recent advances in the direct interaction targets of caffeine in the inhibition of malignancies and will hopefully provide valuable insights into the clinical application of caffeine to the treatment of cancers.


Key words: caffeine, interaction target, adenosine receptor, G6PDH, SIRT3

Copyright © Medicine Research, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States